Biotech Bets: How Abivax and Viking Could Double by 2030

Two clinical-stage biotech companies are positioning themselves for potentially explosive growth if their lead drug candidates clear crucial regulatory hurdles over the next six years. Abivax and Viking Therapeutics represent the high-risk, high-reward profile that defines early-stage pharmaceutical development, where a single successful approval can fundamentally transform a company's valuation and market position.

The Pipeline: Two Promising Drug Candidates

Abivax is focused on developing obefazimod, a drug candidate targeting ulcerative colitis, a chronic inflammatory bowel disease affecting millions globally. The company's clinical development strategy centers on demonstrating obefazimod's efficacy and safety profile through phase trials, with the ultimate goal of securing FDA approval and capturing market share in the inflammatory bowel disease (IBD) sector.

Viking Therapeutics, meanwhile, is advancing VK2735, a promising candidate in the rapidly expanding weight loss treatment category. This positions Viking at the intersection of two significant market trends:

• The explosive growth in GLP-1 receptor agonist therapeutics, exemplified by competitors like Novo Nordisk ($NVO) and Eli Lilly ($LLY)
• The multi-billion-dollar obesity treatment market that has attracted unprecedented pharmaceutical industry attention
• The shift toward oral formulations and novel mechanisms of action beyond existing market leaders

Both companies lack approved commercial products, making them entirely dependent on clinical trial success and regulatory validation.

Market Context: A Sector Primed for Growth

The biotech sector has witnessed extraordinary valuations for successful drug developers, particularly in high-demand therapeutic areas. The weight loss treatment market has exploded following the mainstream adoption of semaglutide (Novo Nordisk's Ozempic and Wegovy) and tirzepatide (Eli Lilly's Mounjaro and Zepbound), creating a multi-trillion-dollar addressable market opportunity.

For Viking Therapeutics, VK2735's potential resides in demonstrating meaningful efficacy advantages or novel mechanisms that differentiate it from existing GLP-1 agonists. In a market increasingly crowded with competitors, differentiation through clinical data becomes paramount. Early signals about VK2735's profile have attracted investor interest, though substantial clinical evidence remains pending.

The ulcerative colitis space where Abivax operates remains therapeutically important but less explosive than the obesity market. Approximately 900,000 Americans suffer from ulcerative colitis, with treatment options including biologics and immunosuppressants. The IBD market shows steady demand and relatively inelastic pricing, offering more predictable economics than weight loss treatments, though with smaller peak sales potential.

Both companies operate in regulatory environments that, while rigorously governed, have shown capacity to fast-track promising candidates. The FDA's breakthrough therapy designation pathway allows accelerated development for drugs addressing unmet medical needs, potentially shortening timelines for either company.

The Risk-Reward Calculus: Clinical Reality and Market Expectations

The doubling-by-2030 thesis hinges on several interconnected assumptions:

• Successful clinical trials: Both candidates must demonstrate statistically significant efficacy and acceptable safety profiles in phase trials
• Regulatory approval: FDA clearance must occur within the timeframe without major restrictions or label limitations
• Market adoption: Approved drugs must achieve commercial traction, capturing meaningful market share against established and emerging competitors
• Valuation expansion: Post-approval valuation multiples must expand as companies transition from clinical-stage to commercial entities

Historically, clinical-stage biotech companies face substantial execution risk. While successful approvals can drive 3-5x returns or greater, failed trials typically result in severe value destruction. The risk profile for Abivax and Viking Therapeutics reflects this reality—investors are essentially pricing in a significant probability of clinical or commercial failure.

The competitive landscape adds complexity. In weight loss treatments, Viking Therapeutics competes against entrenched players with massive scale and distribution advantages. Novo Nordisk ($NVO) and Eli Lilly ($LLY) have already established market dominance and continue expanding their pipelines. For Abivax, the IBD market, while less crowded than obesity, includes established biologics from AbbVie ($ABBV), Janssen (Johnson & Johnson subsidiary), and others with proven track records.

Investor Implications: Weighing Opportunity Against Risk

For growth-oriented investors, Abivax and Viking Therapeutics represent optionality plays rather than core holdings. These companies essentially function as leveraged bets on drug development success. The potential for doubling reflects:

• Clinical validation premium: Positive phase trial data typically drives 30-100% single-day rallies and sustainable revaluations
• Regulatory milestone events: FDA breakthrough designations, priority review grants, and approval announcements create catalysts
• Market expansion potential: Successful obesity drugs have demonstrated market sizes exceeding initial estimates as off-label use expands
• Acquisition potential: Larger pharmaceutical companies routinely acquire successful clinical-stage programs, sometimes at premiums

Conversely, investors must acknowledge the downside risks:

• Trial failures: Inadequate efficacy data or safety signals can erase 50-90% of value
• Competitive pressure: Even successful approvals may struggle to gain market share against better-capitalized competitors
• Financing requirements: Clinical-stage companies typically require substantial capital raises, potentially diluting existing shareholders
• Regulatory setbacks: FDA feedback, delayed approvals, or restrictive labeling can fundamentally alter commercial prospects

These stocks represent venture capital-like investment profiles dressed in publicly-traded securities. They suit investors with high risk tolerance and appropriate portfolio positioning, not those seeking stability or income.

Looking Ahead: Six-Year Catalysts

The pathway to a doubling by 2030 requires successful execution across multiple years and numerous inflection points. Key milestones to monitor include:

• Abivax: Upcoming phase trial readouts for obefazimod, FDA interaction meetings, and regulatory feedback
• Viking Therapeutics: VK2735 clinical trial progression, competitive comparisons emerging from literature, and any emerging safety or efficacy signals

Both companies' trajectories will also depend on macroeconomic conditions, biotech sector sentiment, and capital availability for clinical-stage companies. The sector has experienced substantial valuation volatility, particularly around interest rate changes and funding sentiment shifts.

For patient investors who believe in these companies' science and are comfortable with binary outcomes, the next six years present an intriguing opportunity. However, this remains a high-conviction, high-risk investment profile requiring thorough due diligence and appropriate portfolio allocation. The biotech sector's history suggests that while doubling is achievable for winners, the journey involves substantial volatility and real probability of total capital loss.